Ropivacaine 0.25% Versus Bupivacaine 0.25% for Continuous Epidural Analgesia in Labor: a Double-blind Comparison
Overview
Affiliations
We compared the effects of continuous epidural infusion of ropivacaine 0.25% with bupivacaine 0.25% on pain relief and motor block during labor, and on the neonate. Seventy-six full-term parturients in active labor requiring epidural analgesia were randomly allocated to receive either bupivacaine 0.25% or ropivacaine 0.25%. Fifteen minutes after a loading dose of 10 mL of the study drug, an epidural infusion with the same drug was started at 6-12 mL/h to maintain an adequate block. Top-up doses of 6-10 mL were given as required. At full cervical dilation, the epidural infusion was discontinued. The onset of pain relief (verbal scale), contraction pain (visual analog scale), intensity of motor block (modified Bromage scale), and duration of motor block were not statistically different between the groups. Apgar scores at 1 and 5 min after delivery were comparable. There was a higher proportion of the neonates in the ropivacaine group (26/31 = 84%) who had a neurologic and adaptive capacity score (NACS) > or = 35 2 h after delivery than in the bupivacaine group (18/29 = 62%). We conclude that ropivacaine 0.25% and bupivacaine 0.25% are equally effective for epidural pain relief during labor. Ropivacaine may have an advantage over bupivacaine regarding neonatal neurobehavioral performance during the first few hours after delivery, although further studies will be required to substantiate this.
Bawdane K, Magar J, Tendolkar B J Anaesthesiol Clin Pharmacol. 2016; 32(1):38-43.
PMID: 27006539 PMC: 4784211. DOI: 10.4103/0970-9185.173350.
Agrawal D, Makhija B, Arora M, Haritwal A, Gurha P J Clin Diagn Res. 2014; 8(10):OC03-6.
PMID: 25478409 PMC: 4253227. DOI: 10.7860/JCDR/2014/9974.4930.
Progress in analgesia for labor: focus on neuraxial blocks.
Ranasinghe J, Birnbach D Int J Womens Health. 2010; 1:31-43.
PMID: 21072273 PMC: 2971703. DOI: 10.2147/ijwh.s4552.
Epidural analgesia for childbirth: effects of newer techniques on neonatal outcome.
Capogna G, Camorcia M Paediatr Drugs. 2004; 6(6):375-86.
PMID: 15612838 DOI: 10.2165/00148581-200406060-00005.
Benefit-risk assessment of ropivacaine in the management of postoperative pain.
Zink W, Graf B Drug Saf. 2004; 27(14):1093-114.
PMID: 15554745 DOI: 10.2165/00002018-200427140-00003.